Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BITS-TO-HCC: Iparomlimab/Tuvonralimab + Bevacizumab + HAIC in BCLC Stage C HCC
NCT07062055Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in hepatocellular carcinoma (HCC), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Jul 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07062055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07062055.